NVAX Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.92 |
| 52 Week High | US$23.86 |
| 52 Week Low | US$3.53 |
| Beta | 2.03 |
| 11 Month Change | -25.36% |
| 3 Month Change | -42.02% |
| 1 Year Change | 54.52% |
| 33 Year Change | -93.41% |
| 5 Year Change | 137.89% |
| Change since IPO | -87.60% |
Recent News & Updates
Recent updates
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Sep 01Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Aug 14
Novavax: Staying Long Despite Coming Up Short In Q2
Aug 13Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
Jul 26Novavax: New Chapter, Questions Remain
Jun 20Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement
May 14Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 13Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely
May 07Novavax: Another Day Older And Deeper In
Mar 02Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry
Mar 02Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00
Mar 01Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems
Feb 23Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel
Sep 06Shareholder Returns
| NVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.2% | -3.5% | -1.0% |
| 1Y | 54.5% | 26.0% | 38.1% |
Return vs Industry: NVAX exceeded the US Biotechs industry which returned 26% over the past year.
Return vs Market: NVAX exceeded the US Market which returned 38.1% over the past year.
Price Volatility
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVAX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NVAX's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVAX fundamental statistics | |
|---|---|
| Market cap | US$1.60b |
| Earnings (TTM) | -US$294.33m |
| Revenue (TTM) | US$987.67m |
1.6x
P/S Ratio-5.4x
P/E RatioIs NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVAX income statement (TTM) | |
|---|---|
| Revenue | US$987.67m |
| Cost of Revenue | US$827.91m |
| Gross Profit | US$159.76m |
| Other Expenses | US$454.09m |
| Earnings | -US$294.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 16.18% |
| Net Profit Margin | -29.80% |
| Debt/Equity Ratio | -39.1% |
How did NVAX perform over the long term?
See historical performance and comparison